The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

The Pharma Data

NOVEMBER 4, 2020

5, 2020 11:00 UTC. NASDAQ: CNCE) today reported financial results for the third quarter of 2020. Our team has diligently and effectively executed on our plan, and I’m pleased that we have achieved our stated 2020 pipeline milestones. CTP-543: An Investigational Treatment for Moderate to Severe Alopecia Areata.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Small Molecule 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. SAN JOSE, Calif. ,

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

NOVEMBER 25, 2020

November 25, 2020 — Under FDA law, approval of a new drug requires substantial evidence of effectiveness and a demonstration of safety for the drug’s intended use(s). The approval of remdesivir ( Veklury ) for the treatment of patients hospitalized with COVID-19 met this legal and scientific standard. Posted: November 2020.

FDA 52

FDA Treatment Hospitals Clinical Trials 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 02:59 UTC. Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $3.00 EVANSTON, Ill.–( About Aptinyx.

Small Molecule 40

Small Molecule Treatment Therapies Production 40

The Pharma Data

OCTOBER 26, 2020

27, 2020 10:45 UTC. –( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2020. 2020. for the third quarter of 2020. . for the third quarter of 2020. KENILWORTH, N.J.–(

Vaccine 40

Vaccine Trials Licensing Licensing 40

The Pharma Data

JANUARY 21, 2021

Dr. Recknor’s trial enrolled their first patient on December 3, 2020. Silmitasertib is a first-in-class small molecule drug that targets CK2 and acts as a CK2-inhibitor. FDA for the treatment of Cholangiocarcinoma. FDA on August 27, 2020 , to Dr. Rayyan at BUMCP to treat a patient with severe COVID-19.

Trials 52

Trials Treatment Small Molecule Hospitals 52

Metabolite Tales Blog

APRIL 10, 2024

Table 1: Small molecule drugs approved by the FDA in 2023 with reported involvement of phase II mechanisms In vitro : In vivo differences Incubation of the SGLT2 (sodium-glucose co-transporter-2) inhibitor bexagliflozin in human liver microsomes points to metabolism through both oxidation and glucuronidation to 6 main metabolites.

Small Molecule 59

Small Molecule FDA Approval FDA Pharmacokinetics 59

The Pharma Data

NOVEMBER 29, 2020

30, 2020 07:00 UTC. Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ? synuclein for the treatment of debilitating protein misfolding disorders such as Parkinson’s disease.”.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

New Drug Approvals

SEPTEMBER 10, 2024

g/mol 1929519-13-0 NBI-1065846 or TAK-041 Phase 2 (S)-2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide Zelatriazin ( NBI-1065846 or TAK-041 ) is a small-molecule agonist of GPR139. Zelatriazin, C 18 H 15 F 3 N 4 O 3 , 392.3 “S180. 46 (Supplement_1): S106–S107. 64 (15): 11527–11542.

Clinical Pharmacology 62

Clinical Pharmacology Small Molecule Pharmacokinetics Pharmaceutical Companies 62

The Pharma Data

MAY 31, 2022

The primary endpoint of LUMA is Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) parts II and III combined score over the treatment period. BIIB122 is an investigational small molecule inhibitor of LRRK2 that was discovered and developed by Denali.

Disease 52

Disease Small Molecule Biosimilars Engineering 52

Drug Discovery World

APRIL 10, 2023

However, the role of modern drug discovery technologies and novel treatment approaches is expected to grow over the next few years. billion) until December 2020 to procure different Covid-19 vaccines. Historically, this has been predominantly driven by generic drugs, with branded generics making up 70-80% of the retail market.

Vaccine 130

Vaccine Pharmaceuticals Drugs Science 130

Drug Discovery World

NOVEMBER 1, 2022

“Based on these findings, Aucentra have further amended the study protocol in light of the recent pharmacology findings to now include twice daily dosing of Auceliciclib for 28 days of each treatment cycle for monotherapy and combination dose escalation arms. The research and academia landscape .

Drugs 130

Drugs Science Therapies Clinical Trials 130

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. 15, 2020 (GLOBE NEWSWIRE) — Athenex, Inc., 15, 2020 (GLOBE NEWSWIRE) — Athenex, Inc., What makes this new therapy particularly exciting is the 5-day course of treatment and its good tolerability. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval FDA Treatment Small Molecule 52

Metabolite Tales Blog

JANUARY 23, 2024

Metabolism of 2023 FDA Approved Small Molecules – PART 1 By Julia Shanu-Wilson 2023 was a fruitful year for drug approvals by the FDA, with a crop of 34 small molecules out of a total of 55 new drugs [1]. References [1] 2023 Novel Small Molecule FDA Drug Approvals.

Small Molecule 52

Small Molecule FDA Approval FDA Pharmacokinetics 52

FDA Law Blog: Biosimilars

JULY 11, 2023

To set the stage for this case, we need to go back to March 2020 , when a new definition of “biological product” threw the world of protein products into a tizzy. And, like it has before , the District Court of D.C. recently grappled with this very question in Ipsen v.

FDA 95

FDA Regulations Production Small Molecule 95

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Target Review

JUNE 12, 2023

With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

DECEMBER 13, 2020

13, 2020 /PRNewswire/ — Senhwa Biosciences, Inc. Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine/Cisplatin compared to Gemcitabine/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma.

Small Molecule 40

Small Molecule FDA DNA Clinical Trials 40

The Pharma Data

MARCH 31, 2023

CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive monoclonal antibody, a protease-degradable linker, and a cytotoxic small molecule monomethyl auristatin E (MMAE). CMG901 is being developed for the treatment of solid tumours that express the cell surface protein Claudin 18.2,

Licensing 40

Licensing Licensing Small Molecule Drugs 40

The Pharma Data

OCTOBER 15, 2020

16, 2020 09:20 UTC. In addition, acquired drug resistance has been reported in patients after treatment with approved TRK protein inhibitors. SAN DIEGO–( BUSINESS WIRE )– Cullgen Inc. , Existing therapies to treat TRK fusions have elicited modest on-target adverse effects, including dizziness and weight gain.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

The Pharma Data

DECEMBER 15, 2020

16, 2020 14:00 UTC. Validated technology platform translates novel molecules from plants into first-in-class medicines. By learning patterns of such bioactivity in molecules from thousands of plants, Enveda’s platform also identifies chemical modifications to create patentable drug candidates.

Small Molecule 52

Small Molecule Production Laboratories Engineering 52

KIF1A

JUNE 30, 2023

KAND and Spasticity : We created this resource to help families understand mechanisms of spasticity in KAND, including considerations between different treatment options. With your support, KIF1A.ORG continues to bring together the expertise and innovation needed to rapidly discover treatments and cures for KAND.

Small Molecule 52

Small Molecule Treatment Doctors Research 52

Drug Target Review

JANUARY 5, 2024

Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemical assays. Epub 20230720. doi: 10.1128/jcm.01269-22. Clin Infect Dis. Epub 20151217.

Small Molecule 59

Small Molecule Drugs Biochemical Assays Regulations 59

The Pharma Data

OCTOBER 27, 2020

“Precise diagnosis is the foundation to formulate effective treatment plans for patients of neurodegenerative diseases. Our goal is to provide country-wide access to 18 F-APN-1607 across China in the future, to enable precise diagnosis, accurate monitoring of disease progression and regression, and early detection and treatment.”

Clinical Trials 40

Clinical Trials Trials Small Molecule Pharmaceutical Companies 40

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule 40

Small Molecule Clinical Trials Production Treatment 40

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

NOVEMBER 18, 2021

— Gilead Exercises Options to Arcus’s Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) — — Arcus to Receive Option Payments Totaling $725 million — Gilead Lores,Inc. Nasdaq GILD) and Arcus Biosciences,Inc.

Research 52

Research Small Molecule Clinical Development Packaging 52

The Pharma Data

OCTOBER 18, 2020

19, 2020 08:02 UTC. DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

OCTOBER 27, 2021

Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. With the introduction of small-molecule medication, we open a new chapter in the fight against neurodegenerative diseases and have the chance to improve the lives of millions of patients drastically.”.

Licensing 52

Licensing Licensing Disease Small Molecule 52

The Pharma Data

JANUARY 24, 2021

Dr. Vickers takes the helm of Faze shortly after the company launched in December 2020 with an $81 million Series A financing. Preclinical and clinical programs at Northern Biologics were acquired by big pharma companies in 2020. In addition to his role as CEO, Dr. Vickers will also join Faze’s board of directors. “We

Pharma Companies 52

Pharma Companies Small Molecule Science Pharmaceuticals 52

The Pharma Data

NOVEMBER 12, 2020

12, 2020 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. The offering is expected to close on November 17, 2020, subject to satisfaction of customary closing conditions. Registration statements relating to these securities have been filed with the Securities and Exchange Commission (“SEC”) and became effective on November 12, 2020.

Small Molecule 40

Small Molecule Clinical Trials Production Treatment 40

The Pharma Data

MARCH 4, 2021

Our goal is to one day bring new treatment options that provide greater seizure control, tolerability and function to DS and LGS patients around the world.”. Advancing New Treatment Options for DS and LGS Patients. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. selective GABA A receptor agonist.

Treatment 52

Treatment Pharmaceutical Companies Clinical Trials Licensing 52

The Pharma Data

OCTOBER 25, 2020

26, 2020 /PRNewswire/ — PTC Therapeutics , Inc. Vatiquinone, developed from PTC’s Bio-e platform, is an investigational oral small molecule that inhibits 15-Lipoxygenase, a key enzyme that regulates oxidative stress and inflammation response pathways underpinning many neurological disease pathologies, including epilepsy. .

Clinical Trials 52

Clinical Trials Trials Small Molecule Regulations 52

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros.

Small Molecule 52

Small Molecule Clinical Trials Clinical Development Production 52

The Pharma Data

OCTOBER 21, 2020

Company is on t rack to s ubmit an IND in the fourth quarter of 2020 and i nitiate a Phase 1 /2 clinical trial for advanced solid tumors in 2021. We look forward to advancing clinical development of KB-0742 to establish the dose, safety and efficacy of this investigational therapy as a potential treatment for MYC-amplified tumors.”.

Small Molecule 40

Small Molecule Clinical Trials Clinical Development Treatment 40

NIH Director's Blog: Drug Development

MAY 21, 2020

Science, 2020 We now know that the immune system of nearly everyone who recovers from COVID-19 produces antibodies against SARS-CoV-2, the novel coronavirus that causes this easily transmitted respiratory disease [1]. Preprint Posted May 5, 2020. [2] 2020 May 18. So, what exactly led up to this latest scientific achievement?

Virus 52

Virus Vaccine Laboratories Small Molecule 52